Overseas Regulator Helps Ipsen Score A First In Australia

 
• By Neena Brizmohun

Ipsen’s tyrosine kinase inhibitor, Cabometyx, is the first product to be registered under a new Australian procedure that aims to get prescription drugs to market faster by using medicine assessments already conducted by comparable overseas regulators.

Earth
Australia is using reports from comparable overseas regulators to support drug registrations • Source: Shutterstock

More from Approvals

More from Product Reviews